Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

CAR-T therapy patients monitored for years in new safety study

NCT ID NCT07474051

Knowledge-focused Sponsor: AvenCell Therapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 178 patients who previously received an AvenCell CAR-T cell therapy for cancers like lymphoma, leukemia, or prostate cancer. Researchers will track delayed side effects, including new cancers or autoimmune issues, for years. No new treatment is given—this is purely a long-term safety check.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CAR-T cell therapy (UniCAR or RevCAR platforms)
What this could lead to
If successful, this study could provide crucial safety data to support the broader use of these CAR-T therapies.
What could go wrong
This is a long-term follow-up study, not a treatment trial. It cannot prove the therapy works, and results depend on patient participation and data quality.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 178 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Jan 2041

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants Who Received an AvenCell CAR-T Cell Therapy

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participant who received an AVC-CAR-T cell therapy within an AVC-sponsored clinical trial. 2. Participant signed written informed consent for the AVC-PERSIST study. Exclusion Criteria: 1. Participant is unable to provide written informed consent. 2. Participant is unable to comply with study requirements in the eyes of the Investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AML (acute myelogenous leukemia) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia B-cell chronic lymphocytic leukemia B-cell neoplasm hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AML (acute myelogenous leukemia) B-cell lymphoma Chronic lymphocytic leukemia Hematologic malignancy Prostate cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Charité Universitätsmedizin Berlin

    Berlin, Germany

  • Klinikum der Universität (LMU) Muenchen

    Munich, Germany

  • Technische Universitaet Dresden - Universitaetsklinikum Carl Gustav Carus

    Dresden, Germany

  • Universitatsklinikum Ulm

    Ulm, Germany

  • Universitätsklinikum Marburg

    Marburg, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.